Drugs / TCR reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T cell
TCR reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T cell
also known as
Allogeneic Power3 (SPPL3) knock-out CD19 CAR-T
Cell therapy targets CD19, SPPL3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06481735 | Feb 2025 → Feb 2027 expected | acute lymphoblastic leukemia | Chinese PLA General Hospital | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TCR reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06481735 ↗ |
| Known as | Allogeneic Power3 (SPPL3) knock-out CD19 CAR-T | “Allogeneic Power3 (SPPL3) knock-out CD19 CAR-T” NCT06481735 ↗ |
| Modality | Cell therapy | “allogeneic Power3 (SPPL3) knock-out CD19 CAR-T cell therapy” NCT06481735 ↗ |
| Target | CD19 | “CD19-targeting CAR-T” NCT06481735 ↗ |
| Target | SPPL3 | “disable the Power3 (SPPL3) gene” NCT06481735 ↗ |